Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Design and development of novel, potent and brain penetrant cyclic LRRK2 inhibitors for the treatment of Parkinson's disease.

Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder, where disease-modifying therapy (DMT) represents a major unmet clinical need. Advances in the understanding of underlying pathogenesis reveal the potential therapeutic value of inhibitors targeting leucine-rich repeat kinase 2 (LRRK2...

Wen-Qing Xu, Tian-Qiang Liu, Xin-Yuan Miao et al. · 0 citations
Review Open access Aug 2026

Small-molecule inhibitors targeting the NLRP3 inflammasome: advances since mid-2023 and future perspectives.

The nod-like receptor protein 3 (NLRP3) inflammasome, a critical component of the innate immune system, governs the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and IL-18 and thereby plays a central role in the pathogenesis of various inflammatory diseases. Its aberrant activation is closely lin...

D. Jia, Yun-Lei Hou, Yue Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.